Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
PharmLaw
CMS Proposes Sweeping Prior Authorization Reforms for Drugs, Expanding Transparency and Electronic Requirements
04/15/2026
Hannah Musick
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare &...
04/15/2026
Pharmacy Learning Network
PharmLaw
DOJ Targets Over $500 Million in Health Care and COVID-19 Fraud Schemes Across Multiple Enforcement Actions
04/08/2026
Hannah Musick
The US Department of Justice (DOJ) has launched sweeping enforcement actions targeting over $500 million in alleged fraud across Affordable Care Act (ACA) enrollment, Medicaid drug billing, and COVID-19 relief programs, highlighting...
The US Department of Justice (DOJ) has launched sweeping enforcement actions targeting over $500 million in alleged fraud across Affordable Care Act (ACA) enrollment, Medicaid drug billing, and COVID-19 relief programs, highlighting...
The US Department of Justice...
04/08/2026
Pharmacy Learning Network

FDA Recalls

News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Albuterol Sulfate Inhalation Solution Recalled for Illegible Labeling
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug Administration (FDA) has issued a Class II recall for albuterol sulfate inhalation solution due to illegible labeling, affecting more than 146 000 unit-dose vials used in respiratory care.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network
News
Epinephrine Injection Recalled for Lack of Sterility Assurance
04/16/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug Administration (FDA) has issued a Class II recall for epinephrine injection due to sterility assurance concerns, affecting more than 80 000 units used in emergency care settings.
The US Food and Drug...
04/16/2026
Pharmacy Learning Network

In the News

PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
News
Memantine Hydrochloride Capsules Recalled for Failed Dissolution Specifications
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for memantine hydrochloride capsules due to failure to meet dissolution specifications.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Semaglutide-Glycine-Cyanocobalamin Injectables Recalled for Lack of Sterility Assurance
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for semaglutide-glycine-cyanocobalamin injectable due to sterility assurance concerns, affecting 91 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network
News
Essential Calming Skin Gel Recalled for Subpotent Drug
04/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug Administration (FDA) has issued a Class III recall for Essential Calming Skin Gel due to subpotent drug, affecting nearly 300 units.
The US Food and Drug...
04/23/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use